BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer

Jae In Park, Jae Hyun Jang, Geun Soo Park, Yunro Chung, Hye Jin You, Jae Hong Kim

Research output: Contribution to journalShort survey

5 Scopus citations

Abstract

Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.

Original languageEnglish (US)
Pages (from-to)373-377
Number of pages5
JournalBMB Reports
Volume51
Issue number8
DOIs
StatePublished - Jan 1 2018

Keywords

  • BLT2
  • Leukotriene B4 receptor-2
  • TNBC
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Fingerprint Dive into the research topics of 'BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer'. Together they form a unique fingerprint.

  • Cite this